Numerous preclinical studies have demonstrated that dual pharmacological inhibition of PI3K and MAPK pathways (via both continuous and intermittent dosing) increased therapeutic efficacy in basal-like BC and melanoma models [128,129]. Here, PIK3CG is linked to melanoma.